Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FSME-IMMUN NEW · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| FSME-IMMUN NEW 0.25 ml | BIOLOGICAL | - |
Inclusion Criteria: Male and female children and adolescents will be eligible for participation in this study if: * they are aged 1 year (from the 1st birthday) to \< 16 years (to the last day before the 16th birthday); * they are clinically healthy, (i. e. the physician would have no reservations...
FSME-IMMUN NEW is being developed for the prevention of tick-borne encephalitis, a viral infection of the central nervous system transmitted by tick bites. It is intended for use in healthy children and adolescents aged 1 to 15 years. The program is in Phase 3 clinical development.
FSME-IMMUN NEW is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor responsible for the clinical development program for this tick-borne encephalitis candidate.
FSME-IMMUN NEW is in Phase 3 clinical development. It is an investigational product and has not been approved by the FDA. The program includes one completed Phase 3 trial, with no active trials currently listed.
FSME-IMMUN NEW has been studied in one Phase 3 trial, NCT00161863, titled Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years. The trial is completed and enrolled participants in Austria, Germany, and Poland.
FSME-IMMUN NEW is an investigational monoclonal antibody developed by Pfizer, Inc. for tick-borne encephalitis. It is in Phase 3 development and has been evaluated in healthy children and adolescents aged 1 to 15 years in a completed safety study.